Both the companies are subsidiaries of Japan-based firm Terumo. The latest move is intended to create a single business that is set to focus on aortic and vascular implants segment.
With combined revenue of approximately $200m and more than 1,100 employees, Terumo Aortic will work towards the development of devices to treat aortic disease.
In addition, the organisation plans to generate an integrated research and innovation strategy to potentially expand the market for aortic and vascular implants.
Terumo Aortic president Paul Holbrook said: “This coming together of two organisations with highly advanced technologies will be transformative for physicians and the patients they serve.
“We have woven together the products, services and expertise offered by our teams in Europe and the US, enabling clinicians to meet the unique needs of their patients and redefine the treatment of aortic disease.”
Vascutek and Bolton decided to retain their primary research and manufacturing facilities in Glasgow, Scotland and Sunrise, Florida.
Together, the firms are set to provide a portfolio of advanced technologies such as abdominal, cardiothoracic and peripheral surgical grafts, along with hybrid and catheter-based stent graft systems for abdominal and thoracic aortic aneurysms.
Founded in 1921, Terumo is a medical device firm that acquired Vascutek in 2002 and Bolton Medical in 2017. It employs a total of more than 22,000 people.